Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Interventional Cardiologists (US)

Council Members in this Study Group: 436

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Charles O'Shaughnessy

Director of Interventional Cardiology
NORTH OHIO HEART CENTER, INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Charles O'Shaughnessy, MD, is the Director of Interventional Cardiology at North Ohio Heart Center, Ohio. Dr. O'Shaughnessy's clinical interests are in interventional cardiology including balloon angioplasty, laser directional atherectomy, stent placement,...

Paul Gurbel

Director of Cardiovascular Research
Sinai Hospital of Baltimore, Inc.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Paul Gurbel, MD, is Director of Cardiovascular Research at the Center for Thrombosis Research at Sinai Hospital of Baltimore. Dr. Gurbel has authored over 100 peer-reviewed papers related primarily to coronary thrombosis and interventional cardiology....

Rohit Arora, Professor of Medicine, Finch University of Health Science-Chicago Medical SchoolRohit Arora

Professor of Medicine
Finch University of Health Science-Chicago Medical School
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Rohit Arora, MD, FACC, FAHA, FASCI, FACP, is Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Previously,...

Ramin Ebrahimi

Director of Cardiac Catheterization Lab
Wadsworth VA Medical Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Ramin Ebrahimi, MD, is Associate Clinical Professor at the University of California in Los Angeles. He is also Director of the Cardiac Catheterization Laboratory and Assistant Director of Nuclear Cardiology at the Wadsworth VA Medical Center. Dr. Ebrahimi’s...

Jesse Sethi

Cardiologist/ Electrophysiologist
JOSEPH A. CAPLAN, M.D., P.C.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Jesse Sethi, MD, FACC, is a Cardiologist and Electrophysiologist at Cardiac Solutions, a private practice in Arizona. Dr. Sethi has expertise in electrophysiology procedures such as pacemakers, defibrillators (ICDs), biventricular ICDs, cardiac resynchronization...

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Risk Versus Benefit

November 23, 2007

Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com

The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.

Good device but not much improvement.

August 31, 2007

St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com

The repositioning of the hole, also present with the VIP version is a mild improvement to decrease sheath manipulation. Otherwise the device has not changed much in the past few years. While a very good device in general, its primary limitaions listed below still remain. 1. not allowing re-access at the previous access site within 90 days of the index procedure  2. inability to promote means for primary healing of the arteriotomy site (primary healing results in much less scar formation and secondary healing that angioseal provides) and 3. relying on an intravascular component for deployment that stays within the vessel for weeks prior to its resolution  Newer devices such as the STARCLOSE that also are easy to deploy, rely on no intravascular components and potentially provide much better healing process may be the way of future.   

Warning: You Get What You Pay For!

August 21, 2006

Retail Medical Clinics Draw Patients & Payers | www.managedcaremag.com

Key issues of importance from this article:

Are PAs and NPs well trained enough to provide independent care?
How can these retail clinics be used effectively?
Are these clinics a flash in the pan or a glimpse into the future of medical care?        

Cutting Doctors Fees Would be Disastrous

August 18, 2006

Doctors to Get 5 Percent Cut in Medicare | www.washingtonpost.com

- The issue is more important than the article itself.
- Costs of providing care to Medicare patients in the United States increase exponentially every year.
- Receiving a cut in fees is unjust and not a viable option for many physicians' practices.
- Access to care for Medicare beneficiaries could be unnecessarily but significantly hampered if Congress does not fix the Medicare payment formula.

Generic Clopidogrel: A Boon to Patients and Providers

August 18, 2006

Mixed thoughts on how generic clopidogrel might impact patients, providers | www.theheart.org

- This article summarizes the development of generic clopidogrel by Apotex Corp
- Patient compliance with and use of clopidogrel may increase significantly as a result of the introduction of the Apotex generic and resulting pricing pressure
- The implications of safe and successful drugs produced abroad and sold in the United States are huge.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Division Head
  • Partner
  • Owner